E2022 Patch Formulation Multiple Dose Study

NCT01450839 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: E2022
DRUG: Placebo

Sponsor

Eisai Co., Ltd.